Identification of Multivariable microRNA and Clinical Biomarkers Panels to Predict Imatinib Response in Chronic Myeloid Leukemia at Diagnosis

Imatinib Mesylate (IM) was once hailed as the magic bullet for chronic myeloid leukemia (CML) and remains a front-line therapy for CML to this day alongside other tyrosine kinase inhibitors (TKIs). However, TKI treatments are rarely curative and while they demonstrate efficacy in managing the diseas...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.4547-4547
Hauptverfasser:	Wu, Andrew, Yen, Ryan, Grasedieck, Sarah, Lin, Hanyang, Nakamoto, Helen, Forrest, Donna L., Eaves, Connie J., Jiang, Xiaoyan
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!